drugset / Trial / NCT05305872

Gandouling in the Treatment of Wilson's Disease

NCT05305872

Phase 4 Unknown 240 enrolled Jun Li
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.

Timeline

Start
2023-01-01
Primary completion
2023-03-01
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zinc gluconate Small molecule

Indications